🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New in Leukemia Journal : Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors nature.com/articles/s4137… #leusm

Acalabrutinib with BR for Mantle Cell Journal of Clinical Oncology Randomized phase 3 (ECHO) Previously untreated mantle cell lymphoma pts Acalabrutinib + bendamustine + rituximab (BR) vs. placebo + BR. Both with rituximab maintenance CR: 66.6% vs. 53.5% mPFS: 66.4 mos vs. 49.6 mos (HR: 0.73

🗣:🇹🇷/👥️:🇺🇸👨‍👩‍👦💭 Beş yıl sonra kendinizi nerede görmek istersiniz?

Trials, trials, trials... Aiming to beat RCHOP!

Should be my wife's grandma (=Eşimin anneannesi)

🗣️:🇺🇸/🫂:👨‍⚕️🩸🦀 OS in 😷 w/ transplant-eligible poor-risk AML: Worst: TP53 mutation+complex karyotype (CK): (2-y OS: 24.5%) Intermediate: TP53 mutation w/o CK(2-y OS: 47.1%) Best: AML-MDS Related (MR) Gene Mutation (OS: 65.7%) & AML-MR-Cytogenetic Abnormality (OS: 60.1%).

The neoantigens that result from the splicing errors are located inside cancer cells. This required a TCR approach that empowers T cells to peer inside other cells and identify if there are abnormal proteins. “It’s akin to giving T cells X-ray vision,” Dr. Klebanoff says.

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD.

In vivo CAR T-cell therapy offers advantages such as reduced production time, minimized cytokine release, and a lower risk of secondary malignancies, representing a promising advancement in the field.

ASCO25 Novel Aprroaches Regarding DLBCL

CONGRESS | #ASCO25 | POSTER Mehmet Uyanik Mehmet S Uyanik, MD MD Anderson Cancer Center shares efficacy and safety results from a phase II trial (NCT04975919) of 10-day oral decitabine/cedazuridine (ASTX727) plus venetoclax in adult patients with R/R AML (N = 20). The ORR was 45%, and best response

Self Selected Oscar for the Best Slides on ASCO25 goes to Michael D. Jain from Moffitt Cancer Center FL.

Lovely presentation regarding Late Toxicities of CART Cells ASCO 2025 by Dr. Abramson from Mass General.

Rare Complications of CART Cells:

Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory neurotoxicity syndrome neurotoxicities. ow.ly/blvf50W5eJA #clinicaltrialsandobservations #immunobiologyandimmunotherapy

A new Yale study shows for the first time that immune-system T cells are present in the brain, sent by the gut to a region that regulates hunger and thirst — a finding about T-cell physiology “that changes everything,” says one researcher: bit.ly/4mB9O1Q #Yale

🗣:🇹🇷/👥️:👨‍👩‍👦🤣 Bence ulaştırma bakanlığı, kara yolları genel müdürlüğü ve trafik şube el ele verip tüm radarlardan önce John Carpenter'dan "The End" (Tabiri diğerle meşhur Nuri Alço Operasyon Müziği) melodisini çaldırsın sürücülere! https://=hmZS4yMglDMHWh_p…

🧵 Nivolumab-AVD vs BV-AVD in Older cHL (S1826) 🩺🩻 1️⃣ Population: •cHL ≥60y (median 66) advanced stage (III-IV) •99 patients (N-AVD n=50, BV-AVD n=49) 2️⃣ Primary endpoint: 2y PFS •N-AVD 89% vs BV-AVD 64% •HR 0.24 (95% CI 0.09-0.63), p=0.001 3️⃣ OS at 2y: •N-AVD 96% vs

🗣:🇺🇸/👥️:👨‍⚕️🩺🤣 The orientation module on hand hygiene is designed for fellows, assuming their prior knowledge of hand hygiene practices, as outlined below ⤵️

👉👉We report case series of 6 patients with T-ALL/LBL who developed rhabdomyolysis after receiving nelarabine 👉 Check CK if pt develops myalgia, unexplained rise in creatinine while on nelarabine Mehmet S Uyanik, MD Hagop Kantarjian,MD tandfonline.com/doi/full/10.10…